Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Favresse, Julien; Bayart, Jean‐Louis; Mullier, François; Dogné, Jean Michel; Closset, Mélanie; Douxfils, Jonathan

doi:10.1016/j.cmi.2021.05.004

Cited by 64 publications

(51 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a comparison of cancer patients to healthy controls after the first vaccination with BNT162b2, Monin-Aldama et al described rates of seroconversion of 97, 39, and 13% in healthy controls, solid cancer patients, and patients with hematological malignancies, respectively [26]. Indeed, high seroconversion rates of about 95% for healthy individuals after the first vaccination have been confirmed by others across different vaccine types, but with lower antibody titers in older individuals [27][28][29][30].…”

Section: Discussionmentioning

confidence: 91%

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Ghandili

Lütgehetmann

Wiesch

et al. 2021

Cancers

View full text Add to dashboard Cite

Few data are available regarding the efficacy of anti-SARS-CoV-2 vaccines in patients with hematological malignancies, and particular, plasma cell neoplasia. This ongoing single-center study aimed to describe the level of post-vaccination anti-SARS-CoV-2-antibodies depending on B lymphocyte count, current therapy, and remission status of patients with multiple myeloma and related plasma cell dyscrasia, after the first dose of anti-SARS-CoV-2 vaccination. The 82 patients included in this study received SARS-CoV-2 vaccines (including mRNA- and vector-based vaccines) as a routine measure. After the first vaccination, a positive SARS-CoV-2 spike protein antibody titer (SP-AbT) was detected in 23% of assessable patients. SARS-CoV-2 SP-AbT was significantly higher in patients with higher CD19+ B lymphocyte counts. A cut-off value of ≥30 CD19+ B cells/µL was significantly positive correlating with higher SARS-CoV-2 SP-AbT. In contrast, current treatment with anti-CD38-antibodies has led to significantly reduced SP-AbT titers. Furthermore, in multivariable linear regression, higher age and insufficiently controlled disease significantly correlated negatively with SARS-CoV-2 SP-AbT. Conversely, treatment with immunomodulatory drugs did not harm the development of antibody titers. Based on our results, the majority of myeloma patients respond poorly after receiving the first dose of any anti-SARS-CoV-2 vaccination and need booster vaccination.

show abstract

Section: Discussionmentioning

confidence: 91%

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Ghandili

Lütgehetmann

Wiesch

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7] Around the world, massive vaccination campaigns started in early 2021 and data about the immunological response emerged in the literature to document the evolution of humoral response in subjects vaccinated against SARS-CoV-2. [8][9][10][11][12][13][14][15] In the majority of seronegative subjects, antibody response was positive two weeks after the rst dose and the peak response was observed around 28 days. 13,16 The antibody titers were also higher in previously infected individuals compared to seronegative subjects and recent studies found a decline in antibody titers at 3 months.…”

Section: Introductionmentioning

confidence: 99%

“…[8][9][10][11][12][13][14][15] In the majority of seronegative subjects, antibody response was positive two weeks after the rst dose and the peak response was observed around 28 days. 13,16 The antibody titers were also higher in previously infected individuals compared to seronegative subjects and recent studies found a decline in antibody titers at 3 months. 13,17−19 This antibody decline needs to be well-monitored because it may provide important information to support the decision-making on the potential use of a booster dose.…”

Section: Introductionmentioning

confidence: 99%

Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers

Bayart

Douxfils

Gillot

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Data about the duration of humoral response following COVID-19 vaccines are mandatory to establish appropriate population vaccination strategy. This study reports on the antibody decline observed in a population of COVID-19 naïve and COVID-19 positive individuals having received the two dose regimen of the BNT162b2 vaccine. Six months after vaccination, a significant antibody decline was observed in both COVID-19 naïve and positive individuals. The estimated half-life of total and IgG antibodies differs and ranges from several months for total antibodies to only several weeks for IgG antibodies, explaining the significant proportions of participants with non-detectable levels of neutralizing antibodies at 6 months. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus will require appropriate clinical studies. Nevertheless, these data are already important to support the decision-making on the potential use of a booster dose.

show abstract

“…While most available data of BNT162b2 vaccine are on antibodies elicited upon the first vaccine dose in healthy or SARS-CoV-2 previously infected subjects or at early time points following the second dose (18)(19)(20)(21)(22)(23)(24), our study profiling the antibody response and memory B cells up to six months after vaccination contributes to better understand the BNT162b2 vaccine immunogenicity in SARS-CoV-2 naive subjects.…”

Section: Discussionmentioning

confidence: 99%

Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine

Ciabattini

Pastore

Fiorino

et al. 2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 mRNA vaccines have demonstrated high efficacy and immunogenicity, but limited information is currently available on memory B cells generation and long-term persistence. Here, we investigated Spike-specific memory B cells and humoral responses in 145 subjects, up to six months after the BNT162b2 vaccine (Comirnaty) administration. Spike-specific antibody titers peaked 7 days after the second dose and significant titers and neutralizing activity were still observed after six months, despite a progressive decline over time. Concomitant to antibody reduction, Spike-specific memory B cells, mostly IgG class-switched, increased in blood of vaccinees and persisted six months after vaccination. Following in vitro restimulation, circulating memory B cells reactivated and produced Spike-specific antibodies. A high frequency of Spike-specific IgG+ plasmablasts, identified by computational analysis 7 days after boost, positively correlated with the generation of IgG+ memory B cells at six months. These data demonstrate that mRNA BNT162b2 vaccine elicits strong B cell immunity with Spike-specific memory B cells that still persist six months after vaccination, playing a crucial role for rapid response to SARS-CoV-2 virus encounter.

show abstract

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Cited by 64 publications

References 9 publications

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers

Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine

Contact Info

Product

Resources

About